| Title | Clinical and Molecular Evidence of Atovaquone and Azithromycin Resistance in Relapsed Babesia microti Infection Associated With Rituximab and Chronic Lymphocytic Leukemia. |
| Publication Type | Journal Article |
| Year of Publication | 2017 |
| Authors | Simon MS, Westblade LF, Dziedziech A, Visone JE, Furman RR, Jenkins SG, Schuetz AN, Kirkman LA |
| Journal | Clin Infect Dis |
| Volume | 65 |
| Issue | 7 |
| Pagination | 1222-1225 |
| Date Published | 2017 10 01 |
| ISSN | 1537-6591 |
| Keywords | Aged, 80 and over, Amino Acid Sequence, Antiprotozoal Agents, Atovaquone, Azithromycin, Babesia microti, Babesiosis, Drug Resistance, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Rituximab |
| Abstract | Babesiosis treatment failures with standard therapy have been reported, but the molecular mechanisms are not well understood. We describe the emergence of atovaquone and azithromycin resistance associated with mutations in the binding regions of the target proteins of both drugs during treatment of an immunosuppressed patient with relapsing babesiosis. |
| DOI | 10.1093/cid/cix477 |
| Alternate Journal | Clin Infect Dis |
| PubMed ID | 28541469 |
| PubMed Central ID | PMC6248624 |
| Grant List | UL1 TR000457 / TR / NCATS NIH HHS / United States |
Related Faculty:
Lars Westblade, Ph.D.